Jennifer Karin Ocasio

Jennifer Karin Ocasio

Auto-generated profile, based on publicly available information

Jennifer Karin Ocasio

Department of Developmental Neurobiology, St. Jude Children’s Research Hospital, Memphis, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
JOJennifer Karin Ocasio
Jennifer Karin Ocasio
BBBenjamin Babcock
Benjamin Babcock
DMDaniel Malawsky
Daniel Malawsky
SWSeth J. Weir
Seth J. Weir
LLLipin Loo
Lipin Loo
TGTimothy Gershon
Timothy Gershon
Targeting oncogenic pathways holds promise for brain tumor treatment, but inhibition of Sonic Hedgehog (SHH) signaling has failed in SHH-driven medulloblastoma. Cellular diversity within tumors and reduced lineage commitment can undermine targeted therapy by increasing the probability of treatment-resistant populations. Using single-cell RNA-seq and lineage tracing, we analyzed cellular diversity in medulloblastomas in transgenic, medulloblastoma-prone mice, and responses to the SHH-pathway inhibitor vismodegib. In untreated tumors, we find expected stromal cells and tumor-derived cells showing either a spectrum of neural progenitor-differentiation states or glial and stem cell markers. Vismodegib reduces the proliferative population and increases differentiation. However, specific cell types in vismodegib-treated tumors remain proliferative, showing either persistent SHH-pathway activation or stem cell characteristics. Our data show that even in tumors with a single pathway-activating mutation, diverse mechanisms drive tumor growth. This diversity confers early resistance to targeted inhibitor therapy, demonstrating the need to target multiple pathways simultaneously.

29 April 2023 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
JOJennifer K. Ocasio
Jennifer K. Ocasio
KBKaitlin M. Budd
Kaitlin M. Budd
JRJordan T. Roach
Jordan T. Roach
JAJared M. Andrews
Jared M. Andrews
SBSuzanne Baker
Suzanne Baker

31 May 2016 in Cancer Research
Verified
Journal Article
Open access
PDF file
ACAndrew J. Crowther
Andrew J. Crowther
JOJennifer K. Ocasio
Jennifer K. Ocasio
FFFang Fang
Fang Fang
JMJessica Meidinger
Jessica Meidinger
JWJaclyn Wu
Jaclyn Wu
TGTimothy Gershon
Timothy Gershon
While treatments that induce DNA damage are commonly used as anticancer therapies, the mechanisms through which DNA damage produces a therapeutic response are incompletely understood. Here we have tested whether medulloblastomas must be competent for apoptosis to be sensitive to radiotherapy. Whether apoptosis is required for radiation sensitivity has been controversial. Medulloblastoma, the most common malignant brain tumor in children, is a biologically heterogeneous set of tumors typically sensitive to radiation and chemotherapy; 80% of medulloblastoma patients survive long-term after treatment. We used functional genetic studies to determine whether the intrinsic apoptotic pathway is required for radiation to produce a therapeutic response in mice with primary, Shh-driven medulloblastoma. We found that cranial radiation extended the survival of medulloblastoma-bearing mice and induced widespread apoptosis. Expression analysis and conditional deletion studies showed that Trp53 (p53) was the predominant transcriptional regulator activated by radiation and was strictly required for treatment response. Deletion of Bax, which blocked apoptosis downstream of p53, was sufficient to render tumors radiation resistant. In apoptosis-incompetent, Bax-deleted tumors, radiation activated p53-dependent transcription without provoking cell death and caused two discrete populations to emerge. Most radiated tumor cells underwent terminal differentiation. Perivascular cells, however, quickly resumed proliferation despite p53 activation, behaved as stem cells, and rapidly drove recurrence. These data show that radiation must induce apoptosis in tumor stem cells to be effective. Mutations that disable the intrinsic apoptotic pathways are sufficient to impart radiation resistance. We suggest that medulloblastomas are typically sensitive to DNA-damaging therapies, because they retain apoptosis competence. Cancer Res; 76(11); 3211–23. ©2016 AACR.

1 January 2019 in Development
Verified
Journal Article
Closed access
PDF file
JOJennifer K. Ocasio
Jennifer K. Ocasio
RBRolf Dale P. Bates
Rolf Dale P. Bates
CRCarolyn D. Rapp
Carolyn D. Rapp
TGTimothy Gershon
Timothy Gershon
Cerebellar development requires regulated proliferation of cerebellar granule neuron progenitors (CGNPs). Inadequate CGNP proliferation causes cerebellar hypoplasia whereas excessive CGNP proliferation can cause medulloblastoma, the most common malignant pediatric brain tumor. Although sonic hedgehog (SHH) signaling is known to activate CGNP proliferation, the mechanisms downregulating proliferation are less defined. We investigated CGNP regulation by GSK-3, which downregulates proliferation in the forebrain, gut and breast by suppressing mitogenic WNT signaling in mouse. In striking contrast to these systems, we found that co-deleting Gsk3a and Gsk3b blocked CGNP proliferation, causing severe cerebellar hypoplasia. The GSK-3 inhibitor CHIR-98014 similarly downregulated SHH-driven proliferation. Transcriptomic analysis showed activated WNT signaling and upregulated Cdkn1a in Gsk3a/b-deleted CGNPs. Ctnnb co-deletion increased CGNP proliferation and rescued cerebellar hypoproliferation in Gsk3a/b mutants, demonstrating physiological control of CGNPs by GSK-3, mediated through WNT. SHH-driven medulloblastomas similarly required GSK-3, as co-deleting Gsk3a/b blocked tumor growth in medulloblastoma-prone SmoM2 mice. These data show that a GSK-3/WNT axis modulates the developmental proliferation of CGNPs and the pathological growth of SHH-driven medulloblastoma. The requirement for GSK-3 in SHH-driven proliferation suggests that GSK-3 may be targeted for SHH-driven medulloblastoma therapy.

1 June 2020 in Bioinformatics
Verified
Journal Article
Open access
PDF file
EAEmanuele Aliverti
Emanuele Aliverti
JTJeffrey L Tilson
Jeffrey L Tilson
DFDayne L Filer
Dayne L Filer
BBBenjamin Babcock
Benjamin Babcock
ACAlejandro Colaneri
Alejandro Colaneri
DDDavid B Dunson
David B Dunson
Low-dimensional representations of high-dimensional data are routinely employed in biomedical research to visualize, interpret and communicate results from different pipelines. In this article, we propose a novel procedure to directly estimate t-SNE embeddings that are not driven by batch effects. Without correction, interesting structure in the data can be obscured by batch effects. The proposed algorithm can therefore significantly aid visualization of high-dimensional data. The proposed methods are based on linear algebra and constrained optimization, leading to efficient algorithms and fast computation in many high-dimensional settings. Results on artificial single-cell transcription profiling data show that the proposed procedure successfully removes multiple batch effects from t-SNE embeddings, while retaining fundamental information on cell types. When applied to single-cell gene expression data to investigate mouse medulloblastoma, the proposed method successfully removes batches related with mice identifiers and the date of the experiment, while preserving clusters of oligodendrocytes, astrocytes, and endothelial cells and microglia, which are expected to lie in the stroma within or adjacent to the tumours. Source code implementing the proposed approach is available as an R package at https://github.com/emanuelealiverti/BC_tSNE, including a tutorial to reproduce the simulation studies. aliverti@stat.unipd.it

26 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JOJennifer Karin Ocasio
Jennifer Karin Ocasio
BBBenjamin Babcock
Benjamin Babcock
DMDaniel Malawsky
Daniel Malawsky
SWSeth J. Weir
Seth J. Weir
LLLipin Loo
Lipin Loo
TGTimothy Gershon
Timothy Gershon